Risk of ipsilateral breast event after surgical excision increases over time
the ONA take:
Women with ductal carcinoma in situ (DCIS) who undergo surgical resection without radiation have an increased risk of developing recurrence of DCIS or invasive disease, and that risk increases over time.
A prospective clinical trial sought to determine the 12-year risk of an ipsilateral breast event (IBE) in women with DCIS of the breast treated with lumpectomy without radiation. The results were presented in part at the San Antonio Breast Cancer Symposium.
Study participants were enrolled into two cohorts, not randomly assigned. Cohort 1 was 561 patients with low- or intermediate grade DCIS, tumor size 2.5 cm or smaller. Cohort 2 was 104 patients with high-grade DCIS, tumor size 1 cm or smaller.
Patients underwent excision of the DCIS tumor with a minimum negative margin width of at least 3 mm, and 30% of the patients received tamoxifen (not randomly assigned). An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast. Patients were followed for a median of 12.3 years. There were 99 IBEs, of which 51 were invasive.
Results show that 12-year rates of developing an IBE was 14.4% for cohort 1 and 24.6% for cohort 2; 12-year rates for developing an invasive IBE were 7.5% in cohort 1 and 13.4% in cohort 2. Study cohort and tumor size were significantly associated with risk for IBE.
Women with ductal carcinoma in situ who undergo surgical resection without radiation have an increased risk of developing recurrence.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|